Home › Research › Health systems and care delivery
Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study
Saumur TM, Ashraf H, Mathers KE, Wagner BL.. medRxiv, 2026-01-19
Topic: Drug trials: efficacy and safety
Plain-language summary
Objectives To characterize contemporary pharmacologic treatment patterns for Alzheimer’s disease and related dementias (ADRD) among U.S. long-term care residents and to examine facility- and resident-level factors associated with treatment. Results Overall, 72.5% of residents with ADRD received ≥1 pharmacologic treatment recommended for ADRD. Diagnoses for other chronic conditions as well as specific ADRD subtypes strongly impacted probability of treatment; diabetes and hyperlipidemia were associated with lower odds of treatment, whereas ADRD subtypes strongly predicted treatment. Conclusions and Implications More than one-quarter of residents with ADRD remain untreated with guideline-recommended pharmacotherapy, and treatment varied significantly by non-clinical predictors. These findings underscore the need to investigate and understand possible treatment disparities, optimize polypharmacy management, and discover new ADRD treatments, as current options are often ineffective with many side effects. Comorbidities of diabetes and hyperlipidemia were associated with lower odds of receiving ADRD treatment, suggesting concerns related to adverse drug reactions and competing clinical priorities. The use of cognitive and disease-modifying therapies was low compared to behavioral/psychiatric medications; this finding suggests a need for more effective and safe drugs that target the root causes of ADRD opposed to the behavioral and psychiatric complications. Taken together, the results of this study call for targeted interventions to address disparities in treatment, enhanced clinical decision-making support regarding polypharmacy, and improved pharmacological options for those with ADRD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Saumur, T. M., Ashraf, H., Mathers, K. E., & Wagner, B. L. (2026). Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study. medRxiv. https://doi.org/10.64898/2026.01.16.25342403
Vancouver
Saumur TM, Ashraf H, Mathers KE, Wagner BL. Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study. medRxiv. 2026. doi:10.64898/2026.01.16.25342403.
BibTeX
@article{saumur2026-69c75fbc,
author = {Saumur, T. M. and Ashraf, H. and Mathers, K. E. and Wagner, B. L.},
title = {{Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.01.16.25342403},
url = {https://doi.org/10.64898/2026.01.16.25342403}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Objectives To characterize contemporary pharmacologic treatment patterns for Alzheimer’s disease and related dementias (ADRD) among U.S. long-term care residents and to examine facility- and resident-level factors associated with treatment.
- Results Overall, 72.5% of residents with ADRD received ≥1 pharmacologic treatment recommended for ADRD.
- Diagnoses for other chronic conditions as well as specific ADRD subtypes strongly impacted probability of treatment; diabetes and hyperlipidemia were associated with lower odds of treatment, whereas ADRD subtypes strongly predicted treatment.
- Conclusions and Implications More than one-quarter of residents with ADRD remain untreated with guideline-recommended pharmacotherapy, and treatment varied significantly by non-clinical predictors.
- These findings underscore the need to investigate and understand possible treatment disparities, optimize polypharmacy management, and discover new ADRD treatments, as current options are often ineffective with many side effects.
Study details
- Participants359,801
- Effect size72.5%; 83.9%; 82.3%
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 35 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 62 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 359,801 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 62 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “cholinesterase”
271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.